KR20140094559A - 선천 면역 반응을 증강시키기 위한 화합물 및 방법 - Google Patents

선천 면역 반응을 증강시키기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20140094559A
KR20140094559A KR1020147013668A KR20147013668A KR20140094559A KR 20140094559 A KR20140094559 A KR 20140094559A KR 1020147013668 A KR1020147013668 A KR 1020147013668A KR 20147013668 A KR20147013668 A KR 20147013668A KR 20140094559 A KR20140094559 A KR 20140094559A
Authority
KR
South Korea
Prior art keywords
group
trifluoromethyl
hydrogen
methyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147013668A
Other languages
English (en)
Korean (ko)
Inventor
안나 린지 반카
에릭 그레고리 버로우스
야노스 보티안츠키
존 조지 카탈라노
웬디 후앙 첸
해밀턴 디. 딕슨
마가레트 제이. 가르틀랜드
로버트 하마타케
한스 호프랜드
제씨 다니엘 케이처
크리스토퍼 브룩스 무어
존 브래드포드 샷웰
매튜 데이비드 톨란트
장-필립 테리언
시현 유
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20140094559A publication Critical patent/KR20140094559A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020147013668A 2011-10-21 2012-10-19 선천 면역 반응을 증강시키기 위한 화합물 및 방법 Withdrawn KR20140094559A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US61/549,784 2011-10-21
US201261692431P 2012-08-23 2012-08-23
US61/692,431 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (1)

Publication Number Publication Date
KR20140094559A true KR20140094559A (ko) 2014-07-30

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147013668A Withdrawn KR20140094559A (ko) 2011-10-21 2012-10-19 선천 면역 반응을 증강시키기 위한 화합물 및 방법

Country Status (23)

Country Link
US (1) US20140249143A1 (enExample)
EP (1) EP2768506A4 (enExample)
JP (1) JP2014532626A (enExample)
KR (1) KR20140094559A (enExample)
CN (1) CN103957910A (enExample)
AR (1) AR088793A1 (enExample)
AU (1) AU2012325971B2 (enExample)
BR (1) BR112014008727A2 (enExample)
CA (1) CA2851801A1 (enExample)
CL (1) CL2014001016A1 (enExample)
CO (1) CO6910198A2 (enExample)
CR (1) CR20140175A (enExample)
DO (1) DOP2014000081A (enExample)
EA (1) EA201490610A1 (enExample)
IL (1) IL231894A0 (enExample)
MX (1) MX2014004814A (enExample)
PE (1) PE20141359A1 (enExample)
PH (1) PH12014500865A1 (enExample)
SG (2) SG11201400988SA (enExample)
TW (2) TW201542567A (enExample)
UY (1) UY34406A (enExample)
WO (1) WO2013059559A2 (enExample)
ZA (1) ZA201402392B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
EP3200778A4 (en) * 2014-09-29 2018-05-23 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式
EP3870581B1 (en) 2018-10-23 2023-06-14 Basf Se Tricyclic pesticidal compounds
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
KR20230002396A (ko) 2020-04-14 2023-01-05 바스프 에스이 트리시클릭 살충 화합물
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
CN120916763A (zh) * 2023-04-14 2025-11-07 人福医药美国公司 用于治疗疼痛和相关医学病症的单酰甘油脂肪酶（magl）抑制剂
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59104A (en) * 1979-02-09 1984-02-29 Roussel Uclaf Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US8545732B2 (en) * 2009-03-31 2013-10-01 Daikin Industries, Ltd. Electrode film for polymer actuator element, and polymer actuator element comprising the same
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
TW201333003A (zh) 2013-08-16
AR088793A1 (es) 2014-07-10
CA2851801A1 (en) 2013-04-25
DOP2014000081A (es) 2014-07-15
PE20141359A1 (es) 2014-10-13
EP2768506A4 (en) 2015-08-19
BR112014008727A2 (pt) 2017-04-25
SG10201505664WA (en) 2015-09-29
JP2014532626A (ja) 2014-12-08
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
CO6910198A2 (es) 2014-03-31
CN103957910A (zh) 2014-07-30
IL231894A0 (en) 2014-05-28
PH12014500865A1 (en) 2014-05-26
MX2014004814A (es) 2014-05-27
AU2012325971A1 (en) 2014-04-17
CL2014001016A1 (es) 2015-01-16
US20140249143A1 (en) 2014-09-04
EA201490610A1 (ru) 2014-09-30
AU2012325971B2 (en) 2016-03-31
TW201542567A (zh) 2015-11-16
CR20140175A (es) 2014-06-03
WO2013059559A3 (en) 2013-11-14
SG11201400988SA (en) 2014-07-30
WO2013059559A2 (en) 2013-04-25
UY34406A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
KR20140094559A (ko) 선천 면역 반응을 증강시키기 위한 화합물 및 방법
JP5882329B2 (ja) ＤＮＡ−ＰＫ阻害剤としてのイミダゾ［４，５−ｃ］キノリン
EP1706403B1 (en) Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
JP5694345B2 (ja) Ｔｏｌｌ様受容体の調節因子
TW201141857A (en) Analogues for the treatment or prevention of flavivirus infections
DK2588457T3 (en) PYRAZOLOQUINOLINDERIVATER as DNA-PK inhibitors
EP2477987A1 (en) Modulators of toll-like receptors
WO2016210330A1 (en) Glucose uptake inhibitors
CZ303287B6 (cs) Imidazochinolin substituovaný sulfonamidem nebo sulfamidem a farmaceutická kompozice s jeho obsahem
TW201200522A (en) Analogues for the treatment or prevention of flavivirus infections
WO2018183586A1 (en) Inhibitors of kinase networks and uses thereof
JP2010513286A (ja) ウイルス阻害剤
WO2023244672A1 (en) 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
WO2014121417A1 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN101538267B (zh) 咪唑并[4,5-c]吡啶化合物和抗病毒治疗的方法
RU2800072C1 (ru) Бициклические агонисты стимулятора генов интерферона sting
WO2025128898A1 (en) Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
TW202532074A (zh) Ｓａｒｓ－ｃｏｖ２主要蛋白酶抑制劑
HK1092793B (en) Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140521

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid